<DOC>
	<DOCNO>NCT01735968</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose and/or recommend phase 2 dose combination imatinib BYL719 treatment 3rd line GIST patient .</brief_summary>
	<brief_title>A Dose-finding Study Combination Imatinib BYL719 Treatment 3rd Line GIST Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Male female patient ≥ 18 year age WHO performance status ( PS ) 02 Histologically confirm diagnosis GIST unresectable metastatic .Available tissue specimen : • Doseescalation part : patient must available archival tumor tissue ship course study . In absence archival tumor tissue , patient must agree fresh pretreatment biopsy screening . • Doseexpansion part : patient must available archival tumor tissue ship course study must agree fresh pretreatment biopsy Failed prior therapy imatinib follow sunitinib treatment unresectable metastatic GIST . Note follow specific criterion two part trial : • Doseescalation part : patient fail prior therapy imatinib fail therapy sunitinib . Treatment failure may due either disease progression therapy ( imatinib sunitinib ) intolerance therapy ( sunitinib ) • Doseescalation part patient may additional line therapy imatinib sunitinib doseexpansion part : patient must document disease progression imatinib sunitinib . In addition , patient may two line prior therapy ( i.e . treatment imatinib follow treatment sunitinib ) . • Note : Adjuvant imatinib count prior course imatinib purpose criterion 6 . Radiological ( CT/MRI ) confirmation disease progression ( RECIST criterion ) prior therapy imatinib sunitinib require patient enter Doseexpansion part Previous treatment PI3K inhibitor Patient active uncontrolled symptomatic central nervous system ( CNS ) metastases Note : A patient control asymptomatic CNS metastasis may participate trial . As , patient must complete prior treatment CNS metastases &gt; 28 day ( include radiotherapy and/or surgery ) prior start treatment study receive chronic corticosteroid therapy CNS metastases Severe and/or uncontrolled concurrent medical condition , opinion investigator , could cause unacceptable safety risk compromise compliance protocol ( e.g . acute chronic liver , pancreatic disease , severe renal disease consider unrelated study disease , chronic pulmonary disease include dyspnea rest cause ) Patients diabetes mellitus require insulin treatment and/or clinical sign FPG &gt; 120mg/dL / 6.7mmol/L , history document steroidinduced diabetes mellitus Patient recover grade 1 good adverse event relate previous imatinib and/or sunitinib therapy screening procedure initiate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Imatinib mesylate</keyword>
	<keyword>BYL719</keyword>
	<keyword>GIST</keyword>
</DOC>